Our top pick for
Building a portfolio
Synlogic, Inc is a biotechnology business based in the US. Synlogic shares (SYBX) are listed on the NASDAQ and all prices are listed in US Dollars. Synlogic employs 72 staff and has a trailing 12-month revenue of around USD$545,000.
|52-week range||USD$1.74 - USD$5.11|
|50-day moving average||USD$3.8224|
|200-day moving average||USD$2.9072|
|Wall St. target price||USD$10.71|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.861|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$545,000|
|Return on assets TTM||-22.74%|
|Return on equity TTM||-43.5%|
|Market capitalisation||USD$132.5 million|
TTM: trailing 12 months
There are currently 355,086 Synlogic shares held short by investors – that's known as Synlogic's "short interest". This figure is 11% up from 319,823 last month.
There are a few different ways that this level of interest in shorting Synlogic shares can be evaluated.
Synlogic's "short interest ratio" (SIR) is the quantity of Synlogic shares currently shorted divided by the average quantity of Synlogic shares traded daily (recently around 288687.80487805). Synlogic's SIR currently stands at 1.23. In other words for every 100,000 Synlogic shares traded daily on the market, roughly 1230 shares are currently held short.
However Synlogic's short interest can also be evaluated against the total number of Synlogic shares, or, against the total number of tradable Synlogic shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Synlogic's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Synlogic shares in existence, roughly 10 shares are currently held short) or 0.0152% of the tradable shares (for every 100,000 tradable Synlogic shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Synlogic.
Find out more about how you can short Synlogic stock.
We're not expecting Synlogic to pay a dividend over the next 12 months.
Synlogic's shares were split on a 1:7 basis on 27 August 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synlogic shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Synlogic shares which in turn could have impacted Synlogic's share price.
Over the last 12 months, Synlogic's shares have ranged in value from as little as $1.74 up to $5.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Synlogic's is 1.7905. This would suggest that Synlogic's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Steps to owning and managing PNRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing PINC, with 24-hour and historical pricing before you buy.
Steps to owning and managing POAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTS, with 24-hour and historical pricing before you buy.
Steps to owning and managing PTMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPOP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLYA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAGP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.